SERVIFY
5.8.2021 07:32:13 CEST | Business Wire | Press release
Servify , a leading provider of Extended Care and Product Protection solutions using its global, AI-enabled, digital platform, has announced hiring of senior leaders across regions and functions to drive its global expansion. Arun Verma, MS Kalsi, Kevin Cundiff, Edward Lee, Swetha Prashant, Peter Duesing, Sanghoon (Sam) Kwon, Hussein Hussein and Sergey Odinets have all been hired to bolster various verticals and regions within the organisation.
Arun Verma, with more than 20 years of experience, was appointed as the Chief Human Resources Officer . He has championed impressive success in people management across distinctly diverse industries such as Technology & Services, Finance, Management Consulting & FMCG. He worked as CHRO and Head of Administration of Beetel before Servify, and with the likes of Xerox India, McKinsey & Co., Reliance Capital Limited, and CavinKare in the past.
Makhan Singh Kalsi, also known as M S Kalsi, joins Servify as its Chief Service Officer after previously serving as the Chief Operations Officer for Digicare, a Quess Group Company. During his three years there, he scaled their operations multi-fold, with his enviable brand relationships and market reputation. He has also worked with LeEco, Samsung, Nokia, Canon, and Network Ltd in the past in various senior management positions.
Swetha Prashant joined Servify as Group General Counsel and shall be working closely with the leadership team to help scale and reinforce Servify’s legal capabilities. Swetha, a former partner of J. Sagar Associates (a leading law firm), has been practising law for more than 14 years with extensive experience in representing and advising both domestic and international clients in relation to cross border investments, M&A, JVs, private equity / venture capital, and general corporate commercial transactions and compliances across diverse sectors.
Kevin Cundiff joins Servify’s North American operations as Vice President, Partners & Account Management, and will manage all key partner relations. He has led teams responsible for product placement as well as client acquisition, development and retention in his previous roles and manage all key account relationships in North America. In the past, he has worked in senior positions at Penumbra Brands, uBreakiFix (acquired by Asurion), Fortegra (ProtectCELL parent company) and T-Mobile.
Edward Lee is an insurance industry veteran with a career spanning more than 20 years spearheaded market expansion, product development and regulatory compliance initiatives in support of global manufacturers, distributors and automotive dealer groups in both Canada and the United States for organisations such as Microsoft Corporation, CNH Industrial N.V., SquareTrade, HomeServe USA, Sears, General Motors Corp., Volvo North America, etc. He joins Servify as Vice President and Head of Insurance for North America and will also drive regulatory compliance in the warranty practice globally for Servify.
Sanghoon (Sam) Kwon joined Servify as a Senior Director and will manage Samsung as an OEM account for Servify. He comes with a rich experience which ranges from strategy building to managing global and regional businesses. He worked with Samsung Electronics in Korea and in other geographies in the past & Bolttech just before joining Servify. He is based in Seoul, South Korea.
The Technology function also sees addition of two key hires.
Dr. Peter Duesing, who became part of Servify after its acquisition of German based WebToGo, takes over the position of Vice President - Technology based out of Munich, Germany. He is now responsible for leading engineering teams for our Diagnostics and R&D functions and will also lead our patent portfolio expansion initiatives.
Ghanshyam Varindani joins Servify as Senior Director to lead the Data Engineering function. In previous roles, he has worked in senior roles at AirAsia in Malaysia and TCS leading Data Analytics Strategy and the Business Intelligence Roadmaps.
Additionally, to manage business operations in The Kingdom of Saudi Arabia & Russia, Hussein Hussein and Sergey Odinets have been respectively appointed as Regional Heads. They both have more than a decade of experience each working for top global brands.
“We are fortunate to build a global business that’s also growing massively. I am extremely proud to have these reputed leaders joining me to realise our vision. It’s always great people building great companies, and I am happy that getting great people hasn’t been a problem ever for us,” said Sreevathsa Prabhakar, Founder of Servify, on the expansion of global teams.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005106/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
